治疗神经源性体位性低血压新药屈昔多巴  

Droxidopa,a new drug for the treatment of neurogenic orthostatic hypotension

作　　者：张志叶 王莉 

机构地区：[1]兰州市第一人民医院药剂科,兰州730050 [2]兰州市第一人民医院干部病房,兰州730050

出　　处：《中国新药杂志》2015年第19期2164-2166,2226,共4页Chinese Journal of New Drugs

摘　　要：神经源性体位性低血压是一种慢性疾病,由内在性神经性疾病导致,其症状包括头晕、胸闷、视力模糊、乏力、注意力不集中以及站立时昏厥发作等,严重影响患者的日常活动能力。屈昔多巴是一种合成的氨基酸类似物,2014年2月18日,美国FDA批准其成为首个治疗神经源性体位性低血压的新药。本文对其药理作用、药动学、临床评价、用法用量、药物相互作用和安全性进行综述。Neurogenic orthostatic hypotension is a chronic disorder that is caused by an underlying neurogenic disorder. Symptoms of neurogenic orthostatic hypotension include dizziness,lightheadedness,blurred vision,fatigue,poor concentration,and fainting episodes when a person assumes a standing position. These symptoms often severely limit a person＇s ability to perform routine daily activities that require standing or walking for both short and long periods of time. Droxidopa is a synthetic amino acid analogue. It was approved by FDA as the first drug for the treatment of neurogenic orthostatic hypotension on February 18,2014. A literature search was conducted with the key word droxidopa. The pharmacology,pharmacokinetics,clinical research,dosage,drug interactions and safety of droxidopa were reviewed in this paper.

关 键 词：屈昔多巴 神经源性体位性低血压 抗帕金森病药物 临床研究 

分 类 号：R971.5[医药卫生—药品]